Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP-101 in Dementia-Related Psychosis and Agitation
NCT03044249Phase 2Terminated
- Sponsor
- Mediti Pharma Inc.
- Start
- May 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of oleoyl-estrone in dementia-related psychosis (DRP), agitation, sponsored by Mediti Pharma Inc.. Started May 2017; status: terminated.
02
Drugs
oleoyl-estrone
03
Conditions
dementia-related psychosis (DRP)agitation
Beyond the preview
Go deeper on NCT03044249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03044249.